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Abstract
Background: Physicians need to inform asymptomatic individuals about personalized outcomes of statin therapy for
primary prevention of cardiovascular disease (CVD). However, current prediction models focus on short-term outcomes and
ignore the competing risk of death due to other causes. We aimed to predict the potential lifetime benefits with statin
therapy, taking into account competing risks.
Methods and Findings: A microsimulation model based on 5-y follow-up data from the Rotterdam Study, a population-
based cohort of individuals aged 55 y and older living in the Ommoord district of Rotterdam, the Netherlands, was used to
estimate lifetime outcomes with and without statin therapy. The model was validated in-sample using 10-y follow-up data.
We used baseline variables and model output to construct (1) a web-based calculator for gains in total and CVD-free life
expectancy and (2) color charts for comparing these gains to the Systematic Coronary Risk Evaluation (SCORE) charts. In
2,428 participants (mean age 67.7 y, 35.5% men), statin therapy increased total life expectancy by 0.3 y (SD 0.2) and CVD-
free life expectancy by 0.7 y (SD 0.4). Age, sex, smoking, blood pressure, hypertension, lipids, diabetes, glucose, body mass
index, waist-to-hip ratio, and creatinine were included in the calculator. Gains in total and CVD-free life expectancy
increased with blood pressure, unfavorable lipid levels, and body mass index after multivariable adjustment. Gains
decreased considerably with advancing age, while SCORE 10-y CVD mortality risk increased with age. Twenty-five percent of
participants with a low SCORE risk achieved equal or larger gains in CVD-free life expectancy than the median gain in
participants with a high SCORE risk.
Conclusions: We developed tools to predict personalized increases in total and CVD-free life expectancy with statin therapy.
The predicted gains we found are small. If the underlying model is validated in an independent cohort, the tools may be
useful in discussing with patients their individual outcomes with statin therapy.
Please see later in the article for the Editors’ Summary.
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Current guidelines recommend that asymptomatic individuals
at high cardiovascular disease (CVD) risk be identified for statin
therapy. For this purpose, risk assessment is performed using
prediction models estimating short-term, i.e., 5- to 10-y CVD risk
[1,2]. The higher the predicted CVD risk, the stronger the
recommendation is to initiate statin therapy. This reasoning is
based on solid evidence demonstrating a CVD-risk-reducing effect
for statins [3,4], with an expected larger absolute benefit as CVD
risk increases [5]. For shared decision-making, physicians need to
communicate to the patient personalized information about the
outcomes of statin therapy [6]. Whether the magnitude of the
expected benefit would outweigh the disadvantages of statin
therapy (e.g., side effects, the disutility of taking a pill every day)
can be discussed with the individual in order to reach agreement
on initiation of the drug therapy.
Using the currently available short-term CVD prediction
models for estimating treatment benefits has limitations. First,
statin therapy is generally continued over the remainder of the
course of the lifetime, and information for decision-making should
reflect the expected long-term benefit [7]. Second, short-term risk
reductions are generally small and difficult to interpret by lay
people [8]. Third, competing risk of death due to causes other than
CVD is generally not taken into account. Especially in frail
individuals, who are also at high risk of dying from other causes,
ignoring the competing risk of non-CVD death leads to
overestimation of CVD risk and thus overestimation of the
treatment benefit [9]. Decision models have the ability to
extrapolate short-term follow-up data to a lifetime horizon while
taking into account competing risks of death. Results can be
expressed on a time scale, as gains or losses in (CVD-free) life
expectancy. Life expectancy measures have the advantage that the
aggregated treatment benefits over the full life span can be
represented by a single value. This could provide information
complementary to the conventional communication of risk
reduction, which is limited to the use of fixed time points [10].
Presenting data in various different ways can be helpful for
assessing the certainty about therapy choices and could improve
the quality of decision-making [11].
Our aim was to predict personalized lifetime benefits with statin
therapy for prevention of CVD in asymptomatic individuals
without a history of CVD.
Methods
The Decision Model
We used a previously developed microsimulation state-transi-
tion model, the Rotterdam Ischemic Heart Disease & Stroke
Computer Simulation Model (RISC model), which was built in
TreeAge (version Data Professional, release 10, TreeAge Software)
[12]. The RISC model was developed using 7-y follow-up data
from 3,501 participants of the Rotterdam Study, a population-
based cohort study of individuals aged 55 y and older living in the
Ommoord district of Rotterdam, the Netherlands, followed from
1990 onwards. Only participants with complete data on the
baseline risk factors were used in the development of the RISC
model [13]. Instead of using 7-y hazard rates, more stable 5-y
hazard rates were used for extrapolation to a lifetime horizon in
order to evaluate the lifetime effects of CVD preventive strategies.
In the model, life courses of participants were simulated using
six health states: well, after non-fatal coronary heart disease
(CHD), after non-fatal stroke, after non-fatal CHD and non-fatal
stroke, cardiovascular death, and non-cardiovascular death (see
Figure 1). CHD was defined as having experienced acute
myocardial infarction (International Classification of Diseases,
10th edition [ICD-10] code I21) or having undergone percutane-
ous transluminal coronary angioplasty or coronary artery bypass
grafting. Stroke was limited to non-hemorrhagic and unspecified
strokes (ICD-10 codes I63 and I64) in order to be able to model
the adverse bleeding risk of preventive interventions such as
aspirin therapy separately. Cardiovascular death was defined as
mortality due to hypertensive diseases (ICD-10 codes I10–I15),
ischemic heart disease (ICD-10 codes I20–I25), sudden cardiac
death (ICD-10 codes I46 and I49), congestive heart failure (ICD-
10 code I50), cerebrovascular disease (ICD-10 codes I60–I67),
other arterial disease (ICD-10 codes I70–I79), or sudden death
(ICD-10 code R96). Non-cardiovascular death was defined as
mortality due to all other causes (all other ICD-10 codes). During
5 y of follow-up, 176 CHD events, 127 stroke events, 165 CVD
deaths, and 264 non-CVD deaths occurred in the population of
3,501 participants used to develop the model. Transitions between
health states were individualized using multivariable Cox regres-
sion models, while adjusting for competing risk. Consequently, the
‘‘one-cycle cumulative incidence’’ for each event was calculated as
the ratio of the cumulative hazard of the event of interest, censored
for all other events, to the cumulative hazard of any event,
multiplied by the probability of any event. If constant hazards are
assumed within each cycle, the overall cumulative incidences will
be estimated correctly [14]. The Cox regression models were fitted
in 100 bootstrapped datasets to take into account the parameter
uncertainty of hazard ratios. Each simulated individual entered the
model starting in the well state, with his or her baseline risk profile.
Secular trends in risk factor levels were modeled across the age
span using cross-sectional analyses of baseline data. The individ-
ual’s risk profile at baseline and (if alive) the updated risk profile at
the beginning of each simulated subsequent 5-y period was used as
input for the Cox regression equations. In addition, the Cox
regression equations included age–risk factor interactions. Two life
course scenarios were modeled: ‘‘with statin therapy’’ versus
‘‘without statin therapy.’’ A cycle length of 1 y without discounting
was applied to provide an ‘‘actual’’ life expectancy (for more
information about the RISC model, see Text S1).
Model Validity
The RISC model was constructed with extrapolation of 5-y
predictions based on 7-y follow-up data of 3,501 participants.
However, at the time point of this analysis, we had access to data
with a mean follow-up duration of 11.8 y including 367 CHD
events, 343 stroke events, 494 CVD deaths, and 846 non-CVD
deaths. Therefore, we were able to evaluate the validity of
extrapolation to a longer term by comparing simulated and
observed cumulative incidences at 5 and 10 y of follow-up. We
modeled the life courses of the 3,501 Rotterdam Study partic-
ipants. To assess parameter uncertainty, we calculated 95%
confidence intervals (95% CIs) by consecutively sampling beta
coefficient estimates from the Cox regression analyses performed
in the 100 bootstrapped datasets. Observed cumulative incidences
and 95% CIs were calculated, taking into account competing
death risks and loss to follow-up, using the R cuminc function
available from the mstate package. To assess model discrimina-
tion, we calculated the Harrell’s C-statistic [15] for 10-y CHD
events, stroke events, CVD mortality, and non-CVD mortality.
We adjusted the C-statistic for competing risk by setting the
censoring time to ‘‘infinity’’ (i.e., the maximum follow-up time of
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interest [9].
In addition, we compared the 10-y CVD mortality risk from the
RISC model with the European Society of Cardiology Systematic
Coronary Risk Evaluation (SCORE) charts. Because uncertainty
exists about which SCORE charts to use for Dutch individuals
[16], we compared 10-y CVD mortality risk to the three available
versions: high-risk region, low-risk region, and Dutch recalibrated
SCORE charts. SCORE 10-y CVD mortality risks were
calculated using the equations provided by Conroy et al. [17]
and van Dis et al. [16]. For calculation of the RISC model’s 10-y
CVD mortality risk, we included death by CVD other than stroke
and CHD. The RISC model’s average 10-y CVD mortality risk
estimations and the predictions from each SCORE equation were
plotted by tenths of predicted 10-y CVD mortality from the RISC
model. This was done for only a subset of 1,047 asymptomatic
participants younger than 65 y, meeting the population criteria for
which the SCORE equations are applicable [17]. The 95% CIs of
estimates from the RISC model were calculated by sampling from
the 100 beta coefficient bootstrap replicates as previously
described; the 95% CIs of SCORE predictions were estimated
using non-parametric bootstrapping of the data in each tenth.
Statin Therapy Efficacy
The effect of statin therapy was modeled on the occurrence of
first CHD and stroke events in 2,428 participants who did not use
statin therapy at baseline and were free of CVD (defined as
myocardial infarction, transient ischemic attack, stroke diagnosed
by a physician, and/or a self-reported history of coronary artery
bypass grafting, percutaneous transluminal coronary angioplasty,
or carotid surgery), angina pectoris, intermittent claudication, and
atrial fibrillation. We conservatively assumed that there was no
statin effect on direct transitions from the well state to the
cardiovascular death state, and that the effect of statins was solely
effectuated through their effect on CHD and stroke events. We did
not model additional therapy effects after occurrence of CVD and
did not consider the negligible fatal adverse effects of statin therapy
[18]. The odds ratios for first CHD and stroke events were derived
from a recent meta-analysis (see Table S1) [3]. This meta-analysis
provides effect estimates for statins at doses that are generally
recommended for primary prevention. We assumed that adher-
ence to statin therapy was adequately captured in the statin effect,
as observed in trials with an intention-to-treat analysis. Because
benefits are known to be significant within the first year of
treatment [19], we assumed that the full extent of the statin effect
was achieved within 1 y. In addition, we kept odds ratios constant
over all ages and risk factor levels [3,20].
Personalized Prediction of Lifetime Benefits
We ran the RISC model for the 2,428 participants under the
scenarios with and without statin therapy. To take into account
parameter uncertainty of the Cox regression beta coefficients
underlying the state transition probabilities, 100 linked sets of
coefficients were derived using bootstrapping. Odds ratios with
statin therapy for first CHD and stroke events were randomly
sampled using log-normal distributions based on the reported 95%
CIs. To limit the stochastic error in event occurrences, we used
200 random walks per parameter set. Thus, the RISC model
output consisted of the average lifetime outcomes from 20,000
runs per participant (100 parameter sets6200 random walks)
under the two scenarios (with statin therapy versus without statin
therapy). The uncertainty in the predictions was addressed by
running the RISC model while aggregating at the parameter level.
To show this parameter uncertainty, we present average outcomes
with 95% CIs. Heterogeneity was addressed by running the RISC
model while aggregating at the individual level (Rotterdam Study
participants); the standard deviations (SDs) presented represent the
variation in outcomes across individuals.
Because it is infeasible to run the complicated RISC model for
use in clinical practice, we developed easily programmable
equations that predict the RISC model’s output using the baseline
risk profile of the individual. We used the data generated by the
Figure 1. Schematic representation of the RISC model.
doi:10.1371/journal.pmed.1001361.g001
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above. Depending on the outcome chosen, linear and generalized
linear models with repeated measure statements were used for
constructing these equations. Our primary outcomes were total life
expectancy and CVD-free (CHD/stroke-free) life expectancy. In
addition, we predicted the lifetime risk of developing a first CHD
or stroke event (either fatal or non-fatal), lifetime CHD/stroke
mortality risk, and lifetime total CVD mortality risk. We selected
the following candidate predictors: age, sex, current smoking,
systolic and diastolic blood pressure, hypertension (defined as
either reporting use of antihypertensive medication and/or a
systolic blood pressure $160 mm Hg or a diastolic blood pressure
$95 mm Hg at baseline), total cholesterol, high-density lipopro-
tein (HDL) cholesterol, diabetes mellitus (defined as either
reporting use of antidiabetic medication and/or a random or
post-load serum glucose level $11.0 mmol/l at baseline), serum
glucose, body mass index, waist-to-hip ratio, and serum creatinine.
We chose these variables because they can be reliably and easily
obtained during an office-based health check. Interactions with
statin therapy, age, and sex were tested. Continuous variables were
entered as linear and quadratic terms. Final models were selected
based on the Akaike’s information criterion, which calculates the
log-likelihood penalized for the number of parameters used. All
analyses were performed using R version 2.12.2 (R Foundation for
Statistical Computing, http://www.r-project.org/). For details on
statistical analyses see Text S1.
The predictions of the RISC model have not been indepen-
dently validated and are thus not ready for clinical use. However,
to facilitate validation, we developed a web-based calculator using
the Cleveland Clinic Risk Calculator Constructor (http://rcc.
simpal.com/). The calculator is available at http://www.
erasmusmc.nl/clinical-epidemiology/patientcare/. (Note: as the
calculator is constructed using software hosted by the Cleveland
Clinic, users are asked to agree to the software license of this
organization upon first use.) To illustrate the output of the web-
based calculator, we contrasted the expected lifetime benefits
(expressed in total life expectancy and CHD/stroke-free life
expectancy) with statin therapy to 10-y total CVD mortality risks
for four different risk profiles.
In order to compare gains in total and CHD/stroke-free life
expectancy with office-based assessment of 10-y total CVD
mortality risk, as recommended in the European Society of
Cardiology 2007 guidelines, we constructed color charts similar to
the SCORE risk charts. To show the distribution of the simulated
gains in total and CHD/stroke-free life expectancy according to
SCORE risk estimations we drew scatter plots for the asymptom-
atic population younger than 65 y.
Ethics Statement and Data Access
The Rotterdam Study has been approved by the institutional
review board (Medical Ethics Committee) of the Erasmus Medical
Center and by the review board of the Netherlands Ministry of
Health, Welfare, and Sports. The approval has been renewed every
5 y. The steering committee of the Rotterdam Study does not allow
free sharing of data. Currently, Rotterdam Study data are shared
only within collaborative research projects. Therefore, the data
needed for constructing the web-based calculator unfortunately
cannot be made available for altering to different scenarios.
Results
Model Validity
At year 5, the observed (95% CI) versus simulated (95% CI)
incidences of CHD, stroke, CVD, and non-CVD mortality were
5.0% (4.3–5.8) versus 4.7% (4.2–5.4), 3.6% (3.0–4.3) versus 3.2%
(2.7–3.8), 4.7% (4.0–5.4) versus 4.8% (3.6–6.1), and 7.6% (6.7–8.5)
versus 8.1% (7.1–9.2), respectively. At year 10, these percentages
were 8.5% (7.6–9.5) versus 8.9% (7.9–10.0), 7.6% (6.7–8.5) versus
6.9% (5.9–8.1), 10.9% (9.9–12.0) versus 10.9% (8.6–13.6), and
17.7% (16.5–19.0) versus 17.9% (16.1–20.0). The C-statistic (95%
CI) for CHD was 0.73 (0.70–0.76), for stroke 0.67 (0.64–0.70), for
CVD mortality 0.80 (0.78–0.82), and for non-CVD mortality 0.74
(0.72–0.76).
In the 1,047 participants younger than 65 y, the low-risk region
SCORE equation provided 10-y total CVD mortality estimations
that were most similar to the RISC model output (see Figure S1).
The other two SCORE equations overestimated 10-y total CVD
mortality risk as compared to the RISC model, particularly in the
upper two deciles of SCORE risk estimations (see Figures S2 and
S3).
Population Results
The baseline characteristics of the study population are
summarized in Table 1. In the 2,428 participants (mean age
67.7, SD 8.1, 35.5% men), the average total life expectancy
without statin therapy was 18.3 (SD 6.5) y. The average remaining
life expectancy for females (males) at the age of 60 y was 25.5
(20.4) y, at 65 y was 21.4 (16.7) y, and at 80 y was 10.5 (7.0) y.
Values were less favorable in the original Rotterdam Study cohort
including symptomatic individuals (n=3,501): 25.3 (19.8) y, 21.1
(16.1) y, and 10.2 (6.6) y, respectively. Average CHD/stroke-free
life expectancy in the asymptomatic study population was 16.0
(SD 5.8) y; for females (males), values were 21.8 (16.4) y at the age
of 60 y, 18.4 (13.5) y at 65 y, and 9.6 (5.6) y at 80 y.
Statin therapy resulted in an average gain in life expectancy of
0.3 (95% CI 0.2–0.3) y, with a range of 0.0 to 2.0 y. The gain in
CHD/stroke-free life expectancy with statin therapy was 0.7 (95%
CI 0.5–1.0) y, with a range of 0.1 to 2.8 y. The absolute risk
reduction in CVD incidence with statin therapy was larger than
the decrease in CVD mortality: 6.6% (95% CI 4.5–8.5) versus
3.0% (95% CI 2.0–3.9). The competing other CVD and non-
CVD lifetime mortality risks increased with statin therapy, by
0.9% (95% CI 0.3–1.7) and 2.1% (95% CI 1.3–3.0), respectively.
The effects of statin therapy on the various outcomes are
summarized in Table 2. Both the heterogeneity (SDs and ranges)
and the parameter uncertainty (95% CIs) of gains with statin
therapy are shown.
Personalized Prediction of Lifetime Benefits
For the use of the web-based calculator (http://www.
erasmusmc.nl/clinical-epidemiology/patientcare/), information
on 13 predictors is required: age, sex, smoking, sytolic blood
pressure (mm Hg), diastolic blood pressure (mm Hg), hyperten-
sion, total cholesterol (mmol/l), HDL cholesterol (mmol/l),
diabetes mellitus, serum glucose (mmol/l), body mass index (kg/
m
2), waist-to-hip ratio, and serum creatinine (mmol/l). Ranges for
possible values of continuous predictors were based on the 2.5th
and 97.5th centiles of these variables in the 2,428 participants (see
Table 1). Higher systolic blood pressure, higher total cholesterol,
lower HDL cholesterol, and larger body mass index considerably
increased gains in total and CHD/stroke-free life expectancy with
statin therapy, adjusted for the other co-variables. Increasing age,
however, most notably decreased these gains. Diabetes mellitus
also slightly decreased these gains. Effects of the other predictors
on changes in total and CHD/stroke-free life expectancy were
generally small.
Table 3 presents the 10-y total CVD mortality risks and
lifetime outcomes with and without statin therapy for selected
Personalized Lifetime Benefits with Statins
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a similar or larger gain in (CHD/stroke-free) life years with
statin therapy than participants with a high 10-y risk. For
example, a 55-y-old non-smoking female at a 10-y risk of 2%
could achieve a similar gain in (CHD/stroke-free) life expec-
tancy with statin therapy as a 65-y-old smoking male at a 10-y
risk of 15% (see risk profiles 1 and 2 in Table 3). A 55-y-old non-
smoking male with hypercholesterolemia and hypertension at a
3% 10-y risk can achieve a larger gain in (CHD/stroke-free) life
years with statin therapy than a 75-y-old smoking male with
hypertension and diabetes at a 21% 10-y risk (see profiles 3 and
4i nT a b l e3 ) .
We compared the low-risk region SCORE charts with the
predicted gain in life expectancy with statin therapy (Figure 2).
These charts demonstrate that the 10-y total CVD mortality risk
is highest for elderly smoking individuals with otherwise high risk
factor levels, suggesting that these individuals would benefit most
from statin therapy. Figures 3 and 4, however, demonstrate that
the lifetime benefits of statin therapy are highest for young non-
smoking individuals with high systolic blood pressure and
Table 1. Characteristics of 2,428 participants aged 55 y and older, free of cardiovascular disease and symptoms at baseline.
Characteristics RISC Model Study Population
Age (years) 67.7 (8.1)
2.5th–97.5th range 55–85
Male sex—number (percent) 863 (35.5)
Current cigarette smoking—number (percent) 582 (24.0)
Blood pressure (mm Hg)
Systolic 139.2 (22.4)
2.5th–97.5th range 100–186
Diastolic 74.7 (11.6)
2.5th–97.5th range 53–98
Hypertension—number (percent) 768 (31.6)
Serum cholesterol (mmol/l) 6.7 (1.3)
2.5th–97.5th range 4.5–9.2
Serum HDL cholesterol (mmol/l) 1.4 (0.4)
2.5th–97.5th range 0.8–2.2
Diabetes mellitus—number (percent) 215 (8.9)
Serum glucose (mmol/l) 6.8 (2.5)
2.5th–97.5th range 4.3–13.6
Body mass index (kg/m
2) 26.2 (4.3)
2.5th–97.5th range 20.1–34.3
Waist-to-hip ratio 0.90 (0.09)
2.5th–97.5th range 0.73–1.08
Serum creatinine (mmol/l) 80.6 (15.8)
2.5th–97.5th range 58–110
Data are mean (SD) unless otherwise indicated. Hypertension is defined as either reporting use of antihypertensive medication or having a systolic blood pressure
$160 mm Hg or a diastolic blood pressure $95 mm Hg. Diabetes mellitus is defined as either reporting use of antidiabetic medication or having a serum glucose level
$11.0 mmol/l.
doi:10.1371/journal.pmed.1001361.t001
Table 2. Predicted outcomes and changes with statin therapy for the study population (n=2,428) aged 55 y and older, free of
cardiovascular disease and symptoms at baseline.
Outcome
Mean Baseline
Value (SD)
Mean Absolute
Change (SD)
Minimum; Maximum
Absolute Change
95% CI Absolute
Change
Total life expectancy (years) 18.3 (6.5) +0.3 (0.2) 0.0; +2.0 +0.2; +0.3
CHD/stroke-free life expectancy (years) 16.0 (5.8) +0.7 (0.4) +0.1; +2.8 +0.5; +1.0
CHD/stroke incidence (percent) 33.2 (10.6) 26.6 (1.7) 211.0; 22.8 28.5; 24.5
CHD/stroke mortality (percent) 12.8 (5.3) 23.0 (1.2) 211.5; 20.9 23.9; 22.0
Other CVD mortality (percent) 26.0 (8.7) +0.9 (0.7) 20.8; +6.8 +0.3; +1.7
Non-CVD mortality (percent) 61.3 (10.9) +2.1 (0.9) +0.1; +7.7 +1.3; +3.0
The means, SDs, and ranges are presented to reflect the heterogeneity in the predicted outcomes, and 95% CIs to reflect the parameter uncertainty.
doi:10.1371/journal.pmed.1001361.t002
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a 10-y CVD mortality risk of 1% could achieve a similar gain in
total life expectancy with statin therapy as a 65-y-old smoking
male at a risk of 26%. Figures 5 and 6 plot SCORE risk
estimations versus gains in total and CHD/stroke-free life
expectancy. These plots demonstrate that many individuals with
low SCORE values achieved similar or larger gains than those
with high SCORE values. In Figure 5, 19% and in Figure 6, 25%
of the participants with a SCORE below 0.05 had benefits
greater than or equal to the gains observed in 50% of the
population with a SCORE of 0.05 or more.
Discussion
In this modeling study, we found that in 2,428 asymptomatic
participants, statin therapy resulted in robust, small gains in total
life expectancy and somewhat larger gains in CHD/stroke-free life
expectancy. The expected benefit of statin therapy was determined
by a number of baseline variables. From these variables, we
constructed a web-based calculator and color charts. Once the
underlying model has been independently validated, these tools
can be used for communication of the expected lifetime benefits of
statin therapy in persons aged 55 y and older. Inconsistencies
Table 3. Changes (D) in total life expectancy and CHD/stroke-free life expectancy with statin therapy, compared with predicted
10-y total CVD mortality risk for different risk factor profiles.
Risk Profile
Total Life Expectancy
in Years
CHD/Stroke-Free Life
Expectancy in Years
10-Y Total CVD
Mortality
No Statin D
a No Statin D
b
55-y-old non-smoking R, blood pressure 140/80 mm Hg,
hypertension +, total cholesterol 6.0 mmol/l, HDL cholesterol 1.5 mmol/l,
diabetes 2, glucose 6.0 mmol/l, BMI 25.0, WHR 0.80, creatinine 80 mmol/l
28.9 +0.3 24.9 +1.0 2%
65-y-old smoking =, blood pressure 130/70 mm Hg, hypertension +, total
cholesterol 7.0 mmol/l, HDL cholesterol 1.0 mmol/l, diabetes +, glucose
6.0 mmol/l, BMI 30.0, WHR 1.06, creatinine 90 mmol/l
13.1 +0.4 9.7 +1.0 15%
55-y-old non-smoking =, blood pressure 140/75 mm Hg, hypertension +,
total cholesterol 7.0 mmol/l, HDL 1.3 mmol/l, diabetes 2, glucose
6.5 mmol/l, BMI 27.0, WHR 1.00, creatinine 80 mmol/l
23.9 +0.4 18.7 +1.2 3%
75-y-old smoking =, blood pressure 120/80 mm Hg, hypertension +,
total cholesterol 4.5 mmol/l, HDL 1.0 mmol/l, diabetes +, glucose
6.0 mmol/l, BMI 21.0, WHR 1.00, creatinine 90 mmol/l
6.5 +0.1 6.1 +0.1 21%
Hypertension is defined as either reporting use of antihypertensive medication or having a systolic blood pressure $160 mm Hg or a diastolic blood pressure $95 mm
Hg; diabetes is defined as either reporting use of antidiabetic medication or having a serum glucose level $11.0 mmol/l. Predictions for lifetime CHD/stroke incidence,
CHD/stroke mortality, and total CVD mortality for these risk profiles, are shown in the Table S2.
Conventional conversion factors: to convert HDL and total cholesterol to milligrams per deciliter, divide by 0.0259; creatinine to milligrams per deciliter, divide by 88.4;
glucose to milligrams per deciliter, divide by 0.0555.
aThe gain in total life expectancy in years can be computed as follows: 0.263220.00776age (in years)+0.01386[1 if male sex, 0 if not]20.01156[1 if current cigarette
smoker, 0 if not]+0.00236systolic blood pressure (in mm Hg)20.00186diastolic blood pressure (in mm Hg)+0.04796[1 if hypertension, 0 if not]+0.05486total
cholesterol (in mmol/l)20.14486HDL cholesterol (in mmol/l)20.02186[1 if diabetes mellitus, 0 if not]+0.00866serum glucose (in mmol/l)+0.00996body mass index (in
kg/m
2)20.39896waist-to-hip ratio+0.00256serum creatinine (in mmol/l).
bThe gain in CHD/stroke-life expectancy in years can be computed as follows: 1.885420.03306age (in years)+0.04706[1 if male sex, 0 if not]+0.00496systolic blood
pressure (in mm Hg)20.00406diastolic blood pressure (in mm Hg)+0.11576total cholesterol (in mmol/l)20.36056HDL cholesterol (in mmol/l)20.08996[1 if diabetes
mellitus, 0 if not]+0.00496serum glucose (in mmol/l)+0.01756body mass index (in kg/m
2)20.29156waist-to-hip ratio+0.00236serum creatinine (in mmol/l).
BMI, body mass index; WHR, waist-to-hip ratio.
doi:10.1371/journal.pmed.1001361.t003
Figure 2. Ten-year total CVD mortality risk (percent) predicted by SCORE European low-risk charts. Adapted with permission from the
European Society of Cardiology. Copyright:  2007 Oxford University Press. Note that these charts demonstrate that the 10-y total CVD mortality risk
is highest for elderly smoking individuals with otherwise high risk factor levels, suggesting that these individuals would benefit most from statin
therapy.
doi:10.1371/journal.pmed.1001361.g002
Personalized Lifetime Benefits with Statins
PLOS Medicine | www.plosmedicine.org 6 December 2012 | Volume 9 | Issue 12 | e1001361occurred between the predicted benefits and what can be expected
from the currently recommended 10-y CVD risk assessment.
These inconsistencies were predominantly caused by age, which
acts on lifetime benefits in the opposite direction as its effect on 10-
y CVD risk. Individuals at low 10-y CVD risk may achieve a
similar or even larger gain in total and CHD/stroke-free life
expectancy as those at high 10-y risk.
Most decision tools for CVD prevention in asymptomatic
individuals predict the individual’s risk over a time period ranging
from 5 to 10 y without calculating potential treatment benefits [1].
If treatment benefits are presented, they are usually calculated as
absolute risk reductions without taking into account competing
risks [21–25]. Two decision tools for making choices on statin
therapy were based on Markov models predicting lifetime
outcomes with and without statin therapy [26,27]. The underlying
decision models used data from multiple sources for estimating
CVD events, and age- and sex-specific life tables for competing
death probabilities, which are not necessarily compatible [28]. In
contrast, we used event probability estimations from one data
source. Furthermore, we modeled the occurrence of stroke events
separately from CHD events. Statin therapy has a different effect
on strokes [3], and ignoring this effect would lead to incomplete
estimation and communication of treatment benefits.
Despite these strengths, our results must be interpreted in the
light of some limitations. One limitation is that the RISC model was
used to extrapolate 5-y predictions to a lifetime horizon, which may
be very sensitive to the method chosen [29]. The RISC model
extends cumulative incidence functions by updating age and risk
factor levels using 5-y time intervals. Secular trends in risk factor
levels were modeled across the age span using cross-sectional data,
and thus potential chronological and cohort effects were not taken
into account. We evaluated the validity of these extrapolations with
subsequently available Rotterdam Study data not used in develop-
ing the RISC model and found that the deviations were generally
limited. Developing predictions on longer follow-up data, e.g., 30 y,
would allow for a more comprehensive evaluation of long-term
validity [30]. However, this approach is also questioned, given
chronological changes in CVD event rates and associated risk
factors [31,32], which are less likely to affect validity if more recent
and thus shorter follow-up data are used [33]. We did not evaluate
the model’s performance on predicting outcomes at the individual
level (discrimination) and group level (calibration) using external
data. This would be necessary to investigate to what extent the
personalized predictions are transportable to other settings and
geographical sites, but is beyond the scope of this study.
A second limitation is that the relative risk reducing effect of
statin therapy was kept constant over age and various risk factor
levels. Although a number of observational studies [34] found that
the protective effect of cholesterol lowering on CVD events
decreases in individuals aged 70 to 89 y, this was not confirmed by
experimental research [20,21]. Meta-analyses of statin trials
demonstrate that effects on cardiovascular events are fairly
independent of various risk factor levels [3,35]. These trials,
however, predominantly included participants with elevated risk
Figure 3. The gain in life expectancy (in months) with statin therapy, calculated with the RISC model. Note that these charts
demonstrate that life expectancy (LE) gained with statin therapy is highest for young non-smoking individuals with otherwise high risk factor levels.
doi:10.1371/journal.pmed.1001361.g003
Figure 4. The gain in CHD/stroke-free life expectancy (in months) with statin therapy, calculated with the RISC model. Note that these
charts demonstrate that CHD/stroke-free life expectancy (LE) gained with statin therapy is highest for young individuals with otherwise high risk
factor levels.
doi:10.1371/journal.pmed.1001361.g004
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factor levels were also included, and it is not known whether the
relative risk reduction will be different for these individuals with
normal levels. Thus, we cannot exclude the possibility of a small
overestimation of the statin therapy effect in those with normal risk
levels.
A third limitation is that, although we did account for baseline
statin use, we did not take into account initiation of statin therapy
during follow-up. Omitting this information could lead to an
underestimation of the effect of statin therapy. However, in the
1990s, mass screening for dyslipidemia was not advocated, and
statins were prescribed only to patients with a history of CVD or
with persistent severe dyslipidemia after dietary intervention [36].
Follow-up examinations of the Rotterdam Study population in
1997 revealed that statin use was quite limited [37]. Thus,
underestimation of statin effects due to treatment drop-ins will be
small.
A fourth limitation is that the RISC model’s outcomes did not
perfectly match with all the outcomes as evaluated within statin
trials. Therefore, we were not able to model a statin effect on total
stroke events, and solely modeled an effect on first ischemic and
unspecified stroke. However, these stroke subtypes contribute to
92% of all first stroke events in the Rotterdam Study [38]. In
addition, we did not model a direct statin effect on CVD mortality
by causes other than myocardial infarction and stroke. Although a
reduction in sudden cardiac death—a major component of CVD
mortality—is observed in symptomatic patients treated with
statins, the effect for participants without manifest CVD seems
negligible [39]. Nevertheless, we cannot exclude a small under-
estimation of benefits due to these modeling choices.
Figure 5. Distribution of gains in total life expectancy according to SCORE 10-y total CVD mortality risk (percent). Note that many
individuals with a low SCORE 10-y CVD mortality risk achieved similar or higher gains than those with high SCORE 10-y CVD mortality risk. Ten-year
CVD mortality risks were calculated using the SCORE European low-risk equation in 1,047 participants younger than 65 y without cardiovascular
disease and/or symptoms at baseline.
doi:10.1371/journal.pmed.1001361.g005
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to other populations. The RISC model’s output on cardiovas-
cular mortality was most compatible with a population
resembling inhabitants of a low CVD risk region. This finding
confirms results from another cohort study [16], suggesting
that cardiovascular mortality in Dutch individuals is most
similar to predictions from the low risk region SCORE
equation. In addition, the generalizability of our results also
depends on the competing rate of mortality due to other
diseases. Our estimations of remaining life expectancy for
females and males at the ages of 60, 65, and 80 y, however,
reasonably match estimations for low CVD risk countries as
projected by the Organisation for Economic Co-operation and
Development [40]. Thus, the web-based calculator and color
charts should be used with caution in individuals from regions
with higher CVD risk.
The competing mortality risks from other CVD and non-CVD
causes of death, which were not affected by statin therapy,
sometimes resulted in counterintuitive lifetime outcomes. For
example, age is the most important factor increasing both the
yearly probability of CHD and stroke events, and the fatality of
these events. Thus, age is expected to increase the health benefit of
statin therapy. However, in the Rotterdam Study, age is even
more strongly associated with an increase in yearly mortality from
other causes of death [9]. Subsequently, changes with statin
therapy in lifetime outcomes were smaller with increasing age,
because prevented CHD and stroke events were also increasingly
substituted by other fatal events.
Although the average gain in total life expectancy with statin
therapy may seem small, it is larger than that calculated for some
other preventive interventions targeted at the general population
[29]. One should recognize that gains were much larger in particular
Figure 6. Distribution of gains in CHD/stroke-free life expectancy according to SCORE 10-y total CVD mortality risk (percent). Note
that many individuals with a low SCORE 10-y CVD mortality risk achieved similar or higher gains than those with high SCORE 10-y CVD mortality risk.
Ten-year CVD mortality risks were calculated using the SCORE European low-risk equation in 1,047 participants younger than 65 y without
cardiovascular disease and/or symptoms at baseline. SCORE=Systematic COronary Risk Evaluation.
doi:10.1371/journal.pmed.1001361.g006
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experienced CVD. It should also be acknowledged that with the
benefits of statin therapy, the costs, side effects, and disutility of daily
pill use are likely to be acceptable across various age groups and risk
levels, especially in a ‘‘low statin cost era’’ [41,42]. In addition, we
observed that gains in CHD/stroke-free life expectancy were
generally larger than those in total life expectancy. Two phenomena
can explain thisobservation. First, alarge proportionofthe CHDand
stroke events were not fatal. Gains in CHD/stroke-free life
expectancy are mainly driven by statin effects on non-fatal CHD
and stroke event rates, while gains in total life expectancy are driven
by effects on CHD and stroke death rates. Second, individuals in
whom fatal CHD and stroke events are avoided are alsolikelyto be at
elevated risk for death by other causes. Our finding of a smaller effect
of statin therapy on total life expectancy than on CHD/stroke-free
life expectancy is in agreement with the results from statin trials, in
which generally only modest effects are demonstrated for crude total
mortality risks,while effects on crude CHDand stroke incidence risks
are more pronounced [3].
Currently, statin therapy choices are based on short-term CVD
risk without statin therapy and the expected risk reduction with
statin therapy over the same time period. We converted survival
benefits with statin therapy into total life expectancy and CHD/
stroke-free life expectancy.
We believe that the prediction of statin therapy effects on
(disease-free) life expectancy can be complementary to the 10-y
CVD risk assessment in two ways. First, instead of regarding a
fixed time point, i.e., 10 y, the benefit of statin therapy considering
the entire survival curve can be communicated by primary care
physicians. Second, the benefit of statin therapy is calculated
taking into account competing mortality risks. The potential value
of personalizing the gain in total and CHD/stroke-free life
expectancy with statin therapy is best illustrated by Figures 5 and
6. A substantial number of individuals with 10-y total CVD
mortality risk lower than 5%, for whom statin therapy is generally
not recommended according to current European Society of
Cardiology guidelines, may benefit to the same extent as
individuals with a high risk. A similar pattern will apply to
predictions based on other CVD risk models, such as risk scores
based on the Framingham Study [43,44], because these use the
same risk factors, with effects pointing in equal directions.
When making decisions on statin therapy, the fact that the
benefit in life expectancy diminishes with advancing age may be
considered by physicians, especially in the elderly. If independently
validated, physicians could use the web-based calculator and color
charts to frame survival outcomes in different ways and to discuss
them with the patient in light of the expected duration of statin
use. The longer the life expectancy, and therefore the expected
duration of statin use, the higher the costs and possibility of
adverse effects. Besides the costs averted by CVD prevention,
these important outcomes could influence the decision, but were
not taken into account in our analysis. In addition, it should be
acknowledged that the calculated differences in the personalized
lifetime outcomes may vary across different clinical settings and
are subject to the parameter uncertainty in the underlying decision
model. These caveats would need to be discussed with patients
when they are informed about the benefits of statin therapy.
In conclusion, we demonstrated that life expectancy benefits
with statin therapy can be predicted using an individual’s risk
factor profile. The predicted gains in life expectancy we found are
generally small. If the underlying model is validated in an
independent cohort, the developed tools may be useful in
discussing with patients their individual expected outcomes with
statin therapy. Ideally, communication of personalized outcomes
will ultimately result in better clinical outcomes. Improved
understanding of potential gains will, however, not necessarily
go hand in hand with an improvement in clinical outcomes,
because patients could be less likely to choose statin therapy when
more information on benefits is provided [45]. In addition to an
external validation of our predictions, personalized estimates for
costs and side effects of statin therapy should be included in future
research. Finally, the impact of communicating life expectancy
benefits on satisfaction, behavioral, and clinical outcome measures
should be studied.
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Background. Cardiovascular disease (CVD) affects the heart
and/or the blood vessels and is a major cause of illness and
death worldwide. In the US, for example, coronary heart
disease—a CVD in which narrowing of the heart’s blood
vessels by fatty deposits slows the blood supply to the heart
and may eventually cause a heart attack—is the leading
cause of death, and stroke—a CVD in which the brain’s
blood supply is interrupted—is the fourth leading cause of
death. Established risk factors for CVD include smoking, high
blood pressure, obesity, and high blood levels of a fat called
low-density lipoprotein (‘‘bad cholesterol’’). Because many of
these risk factors can be modified by lifestyle changes and by
drugs, CVD can be prevented. Thus, physicians can assess a
healthy individual’s risk of developing CVD using a CVD
prediction model (equations that take into account the CVD
risk factors to which the individual is exposed) and can then
recommend lifestyle changes and medications to reduce
that individual’s CVD risk.
Why Was This Study Done? Current guidelines recom-
mend that asymptomatic (healthy) individuals whose likely
CVD risk is high should be encouraged to take statins—
cholesterol-lowering drugs—as a preventative measure. Statins
help to prevent CVD in healthy people with a high predicted
risk of CVD, but, like all medicines, they have some unwanted
side effects, so it is important that physicians can communicate
both the benefits and drawbacks of statins totheir patients in a
way that allows them to make an informed decision about
taking these drugs. Telling a patient that statins will reduce his
or her short-term risk of CVD is not always helpful—patients
really need to know the potential lifetime benefits of statin
therapy. That is, they need to know how much longer they
m i g h tl i v ei ft h e yt a k es t a t i n s .H e r e ,t h er e s e a r c h e r su s ea
mathematical model to predict the personalized lifetime
benefits (increased total and CVD-free life expectancy) of statin
therapy for individuals without a history of CVD.
What Did the Researchers Do and Find? The researchers
used the Rotterdam Ischemic Heart Disease & Stroke
Computer Simulation (RISC) model, which simulates the life
courses of individuals through six health states, from well
through to CVD or non-CVD death, to estimate lifetime
outcomes with and without statin therapy in a population of
healthy elderly individuals. They then used these outcomes
and information on baseline risk factors to develop a web-
based calculator suitable for personalized prediction of the
lifetime benefits of statins in routine clinical practice. The
model estimated that statin therapy increases average life
expectancy in the study population by 0.3 years and average
CVD-free life expectancy by 0.7 years. The gains in total and
CVD-free life expectancy associated with statin therapy
increased with blood pressure, unfavorable cholesterol
levels, and body mass index (an indicator of body fat) but
decreased with age. Notably, the web-based calculator
predicted that some individuals with a low ten-year CVD
risk might achieve a similar or larger gain in CVD-free life
expectancy with statin therapy than some individuals with a
high ten-year risk. So, for example, both a 55-year-old non-
smoking woman with a ten-year CVD mortality risk of 2% (a
two in a hundred chance of dying of CVD within ten years)
and a 65-year-old male smoker with a ten-year CVD mortality
risk of 15% might both gain one year of CVD-free life
expectancy with statin therapy.
What Do These Findings Mean? These findings suggest
that statin therapy can lead on average to small gains in total
life expectancy and slightly larger gains in CVD-free life
expectancy among healthy individuals, and show that life
expectancy benefits can be predicted using an individual’s
risk factor profile. The accuracy and generalizability of these
findings is limited by the assumptions included in the model
(in particular, the model did not allow for the known side
effects of statin therapy) and by the data fed into it—
importantly, the risk prediction model needs to be validated
using an independent dataset. If future research confirms the
findings of this study, the researchers’ web-based calculator
could provide complementary information to the currently
recommended ten-year CVD mortality risk assessment.
Whether communication of personalized outcomes will
ultimately result in better clinical outcomes remains to be
seen, however, because patients may be less likely to choose
statin therapy when provided with more information about
its likely benefits.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001361.
N The web-based calculator for personalized prediction of
lifetime benefits with statin therapy is available (after
agreement to software license)
N The American Heart Association provides information
about many types of cardiovascular disease for patients,
carers, and professionals, including information about drug
therapy for cholesterol and a heart attack risk calculator
N The UK National Health Service Choices website provides
information about cardiovascular disease and about statins
N Information is available from the British Heart Foundation
on heart disease and keeping the heart healthy; informa-
tion is also available on statins, including personal stories
about deciding to take statins
N The US National Heart Lung and Blood Institute provides
information on a wide range of cardiovascular diseases
N The European Society of Cardiology’s cardiovascular
disease risk assessment model (SCORE) is available
N MedlinePlus provides links to many other sources of
information on heart diseases, vascular diseases, stroke,
and statins (in English and Spanish)
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